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TO THE EDITOR
The patient is a 25-year-old male who
presented for evaluation and manage-
ment of plaque psoriasis, which had
begun 5 years earlier. Treatment with
topical corticosteroids had not been
particularly helpful, and, because of
the involvement of psoriasis over an
increasing body surface area, systemic
therapy with adalimumab had been
initiated 1 year before. Although
clearing of psoriasis was experienced
early in the course of adalimumab, the
improvement faded. In addition to
psoriasis, the patient reported a history
of alopecia areata (AA) beginning at
around age 2 years, which progressed
to alopecia universalis (AU) by age 18
years. Treatment of the alopecia with
topical corticosteroids had not been
effective, and he had received no other
therapy for it. He had no family
history of either psoriasis or AA, and
his past medical history was otherwise
unremarkable.
On examination, the patient demon-
strated numerous well-marginated pink–
red scaly plaques on the scalp, torso,
and elbows. He had no eyebrows, eye-
lashes (Figure 1a), or facial hair, and no
hair on his arms, legs, torso, axillae, or
groin. Notably, the only prominent hair
growth on the scalp was within areas of
psoriasis (Figure 2a), reminiscent of hair
growth that occurs in areas of irritant
contact dermatitis generated by topical
anthralin (Schmoeckel et al., 1979).
As treatment options for the patient
were considered, we sought a therapeu-
tic agent that could potentially target
both psoriasis and AU simultaneously.
We identified tofacitinib as a promising
agent and began treatment.
Tofacitinib citrate (Xeljanz), formerly
CP-690550 and tasocitinib, is a novel
small-molecule selective Janus kinase
1/3 (JAK 1/3) inhibitor that was FDA-
approved in late 2012 for the treatment
of moderate-to-severe rheumatoid
arthritis (RA). JAK inhibition has myriad
effects on T-lymphocytes, and therefore
it is not surprising that this medication
may be useful in the treatment of many
inflammatory diseases (Pesu et al.,
2005). Indeed, both oral and topical
formulations of tofacitinib have been
demonstrated to be safe and effective
for the treatment of plaque psoriasis
(Boy et al., 2009; Papp et al., 2012;
Mamolo et al., 2013; Ports et al., 2013;
Strober et al., 2013), with additional
clinical trials for psoriasis and other
inflammatory disorders now underway
(clinicaltrials.gov). In the case of
psoriasis, increased interleukin-15 (IL-
15) expression is observed in lesional
skin and may lead to epidermal hyper-
proliferation via keratinocyte apoptotic
resistance (Ruckert et al., 2000).
Tofacitinib, which abrogates IL-15
signaling (Johnston et al., 1995), might
therefore be effective in psoriasis by
normalizing keratinocyte apoptosis
(Ruckert et al., 2000).
In a murine model of AA, a type I cyto-
toxic pathway has been demonstrated
to be responsible for the disease state,
with NKG2D-expressing CD8þ cytoly-
tic T-lymphocytes identified as both
necessary and sufficient for induction
of disease. Upregulation of IL-15
in the outer root sheath of the hair follicle
activates cytolytic T-lymphocytes, which
in turn produce IFNg, leading to activa-
tion of the hair follicle and upregulation
of IL-15, NKG2D ligands, and MHC
molecules, all of which target the hair
Figure 1. Representative photographs of patients eyebrows and eyelashes before treatment and after 8
months. Eyebrows and eyelashes at baseline (a) and after 8 months of therapy (b).
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follicle for attack (Jabbari et al., 2013).
The same group has demonstrated
that systemic treatment with the JAK
inhibitors tofacitinib and ruxolitinib
(a JAK 1/2 inhibitor) prevents the
onset of AA in grafted AA mice
(Dai et al., 2012; Jabbari et al., 2012)
and that topical treatment reverses
AA in these mice (Jabbari et al., 2013).
JAK 1/3 signaling mediates IL-15
activation of T-lymphocytes (Ghoreschi
et al., 2011), explaining the success of
these therapies.
After 2 months of tofacitinib at 5 mg
twice daily (the approved RA dose),
there was some improvement in psor-
iasis with partial hair regrowth on the
scalp (Figure 2b) and face. Given that
higher doses of tofacitinib (up to 15 mg
twice daily) have been shown to be
more effective in psoriasis (Papp et al.,
2012), the dose was increased to 10 mg
in the morning and 5 mg at night. After 3
more months of therapy, there was
complete regrowth of the scalp
hair (Figure 2c) along with significant
regrowth of eyebrows, eyelashes, and
facial hair along with axillary and pubic
hair. After 8 months of therapy, there
was full regrowth of hair at all body sites
(Figures 1b and 2d), except for the arms
and legs, locations where the patient
reports never having more than sparse
hair growth prior to the onset of AU.
Improvement of psoriasis has lagged
behind reversal of alopecia, which is
likely dose-related (Papp et al., 2012).
Although we considered increasing the
dose of tofacitinib, the patient is so
pleased with the regrowth of his hair
(and is not particularly bothered by the
remaining psoriasis) that he has chosen
to continue at the present dose. The
patient has tolerated tofacitinib without
subjective complaints. Laboratory moni-
toring has revealed no abnormalities in
serum creatinine, electrolytes, glucose,
complete blood count, hepatic function,
or lipids.
To our knowledge, this is the first
report of effective pathogenesis-based
therapy for a patient with alopecia uni-
versalis. Although the results in this
patient are provocative, a clinical trial
would more fully and systematically
address the safety and efficacy of tofa-
citinib and other JAK inhibitors in the
treatment of AA and its variants. Aptly,
an open-label pilot study evaluating the
efficacy of ruxolitinib in moderate-
to-severe AA is currently underway
(Mackay-Wiggan, 2014). Given the
potential for serious adverse effects
from oral JAK inhibitors, it would be
particularly useful to explore the use of
topical formulations for these disorders.
The era of biological therapy has
greatly enhanced the ability to make
nuanced therapeutic decisions. With
every new agent, more thoughtful treat-
ment algorithms become possible, per-
mitting better treatment of complex
patients with multiple comorbidities.
As in the case presented herein, see-
mingly disparate diseases with different
pathomechanisms may be affected
positively by a single agent. This case
highlights the interplay between
advances in basic science and thera-
peutics and provides a compelling
example of the ways in which an
increasingly complex understanding of
medicine and ingenuity in treatment
benefit patients.
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IL-17 Induces Inflammation-Associated Gene Products in
Blood Monocytes, and Treatment with Ixekizumab Reduces
Their Expression in Psoriasis Patient Blood
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TO THE EDITOR
Recently, our understanding of pso-
riasis has expanded from a superficial
skin disease to a systemic inflammatory
process that affects multiple organs.
It has been postulated that circulating
high levels of pro-inflammatory cyto-
kines may predispose psoriasis
patients to serious comorbid con-
ditions such as atherosclerosis, psoriatic
arthritis, obesity, and diabetes
(Davidovici et al., 2010). However, the
mechanistic link between increased
circulating cytokine levels and these
comorbid conditions remains to be
established.
IL-17A (IL-17) is known to be a
central cytokine in psoriasis patho-
genesis. We previously reported signi-
ficant clinical improvements in patients
treated with ixekizumab (anti-IL-17A
monoclonal antibody), which were
accompanied by a rapid reversal of
epidermal hyperplasia and dermal infil-
tration of leukocytes (Krueger et al.,
2012). It is known that the level of
IL-17 is elevated in the blood of psoria-
sis patients (Sua´rez-Farin˜as et al., 2012)
but the effects of IL-17 on circulating
leukocytes bearing IL-17 receptors are
not fully understood. Human mono-
cytes highly express both IL-17RA and
IL-17RC, and chemotraffic in response
to IL-17 (Shahrara et al., 2009), and the
activation and recruitment of effector
monocytes are known to have a role in
the pathobiology of a number of systemic
inflammatory diseases, including comor-
bidities associated with psoriasis, such as
atherosclerosis, metabolic regulation in
adipose tissue, and psoriatic arthritis. In
this study we explored the role of IL-17 in
regulating monocyte activities in culture
as well as its impact on systemic inflam-
mation in psoriasis patients treated with
ixekizumab.
First, genomic profiling was per-
formed on normal CD14þ monocytes
treated with IL-17A (200 ng ml1) for
24 hours in culture. Genes that
were induced included pro-inflam-
matory cytokines (41.5-fold, Po0.1),
chemokines, genes associated with
inflammatory response, and molecules
involved in cytokine signal transduction
(Supplementary Table S1a and b
online). We also observed upregulation
of chemokine receptors, which mediate
monocyte chemotaxis (Supplementary
Table S1c online), such as CXCR4 and
CCR2, as well as cell adhesion mole-
cules that mediate the rolling and dock-
ing of monocytes on vascular endo-
thelial cells, including integrin a4, integ-
rin b2, platelet/endothelial cell adhesion
molecule 1, and CD99, which are
known to be critical for plaque forma-
tion in atherosclerosis (Supplementary
Table S1d online). These findings were
confirmed with Ingenuity Pathway Ana-
lysis software, which identified signaling
pathways that were most significantly
affected in monocytes after IL-17
stimulation. The Ingenuity Pathway
Analysis system identified numerous
pathways associated with a pro-inflam-
matory response that were positively
enriched, such as IL-17 signaling,
IL-6/STAT3 signaling, as well as the
leukocyte transendothelial migration
pathway, which includes additional
cell adhesion molecules associated
with platelet accumulation in athero-
sclerosis (Figure 1).
Figure 1. Ingenuity pathway analysis (IPA) software was used to identify altered gene expression in proinflammatory signaling pathways. (a–c) Left panels:
transcriptional changes in monocytes treated with IL-17 (200 ng ml 1) for 24 hours vs. control. (d–f) Right panels: transcriptional changes in the blood
of psoriasis patients after ixekizumab treatment (150 mg week 2 vs. baseline). Gene expression networks that are displayed include (a, d) the IL-17 signaling
pathway, (b, e) the IL-6/STAT3 signaling pathway, and (c, f) leukocyte transendothelial migration. Green designates inhibitions in gene expression; red
designates increases in gene expression. Applies to a–f.
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